PLX Pharma Inc Stock
-
Your prediction
Pros and Cons of PLX Pharma Inc in the next few years
Pros
Cons
Performance of PLX Pharma Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| PLX Pharma Inc | - | - | - | - | - | - | - |
| Ardelyx Inc. | -3.860% | -10.646% | 8.770% | 81.814% | 24.879% | 33.667% | - |
| Evolus Inc | -1.650% | -3.252% | 1.709% | 39.181% | 31.492% | 59.732% | - |
| Salarius Pharmaceuticals Inc. | 2.480% | -8.811% | 2.985% | -70.216% | -25.405% | -98.392% | -99.993% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon a general evaluation of the financial statements, it is apparent that PLX Pharma exhibits characteristics of a biotechnology and medical research company in a growth phase. The company's financials show fluctuations in several areas, including assets, liabilities, and revenues, which is typical for companies in this industry.
Increasing total assets - From 2019 to 2021, the total assets of PLX Pharma increased from $18,502,746 to $76,642,000, a significant growth in a relatively short period of time. This indicates the company's ability to generate and maintain valuable resources, essential for further investments and growth opportunities.
Substantial cash reserves - The cash balance has increased from $14,001,304 in 2019 to $69,392,000 in 2021. This is a positive development as it ensures the company has adequate liquidity and financial stability to fund ongoing research, meet liabilities, and invest in future growth projects.